Exelixis stock kpis
Want to see EXEL full AI Analyst Report?
Revenue by Segment
In Q3 2026, Exelixis reported revenue by segment of $53.77M (Collaboration), $603.15M (Cabometyx) and $1.77M (Cometriq).
Separates revenue into categories like product sales, royalties/collaborations, and other income. For Exelixis, segment-level detail highlights reliance on flagship oncology products versus partner payments, indicating concentration risk, recurring royalty stability, and sensitivity to clinical or patent events.
CABOMETYX is unmistakably the growth engine, delivering sustained, accelerating net‑product revenue while Cometriq and Collaboration are small and lumpy (that Collaboration spike appears one‑off). Management’s guidance trim reflects a slower NET uptake and higher gross‑to‑net deductions—meaning demand looks intact but near‑term realized revenue will be modestly constrained. Low trade inventory and large buybacks signal cash strength and confidence, but the stock’s upside hinges on executing the NET ramp and successful zanzalintinib readouts to diversify reliance on cabozantinib.
EXEL Revenue by Segment
| Period | Collaboration | Cabometyx | Cometriq | United States |
|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $53.77M | $603.15M | $1.77M | ― |
| Q2 2026Jun 30, 2026 | $55.66M | $570.65M | $2.38M | ― |
| Q1 2026Mar 31, 2026 | $55.84M | $552.77M | $2.20M | ― |
| Q4 2025Dec 31, 2025 | $52.09M | $544.73M | $1.85M | ― |
| Q3 2025Sep 30, 2025 | $54.83M | $539.88M | $3.05M | ― |
| Q2 2025Jun 30, 2025 | $48.25M | $517.89M | $2.12M | ― |
| Q1 2025Mar 31, 2025 | $42.16M | $510.87M | $2.41M | $517.18M |
| Q4 2024Dec 31, 2024 | $51.51M | $512.84M | $2.46M | $519.09M |
| Q3 2024Sep 30, 2024 | $61.50M | $475.70M | $2.40M | $481.50M |
| Q2 2024Jun 30, 2024 | $199.60M | $433.30M | $4.20M | $440.50M |
| Q1 2024Mar 31, 2024 | $46.70M | $376.40M | $2.10M | $381.90M |
| Q4 2023Dec 31, 2023 | $50.30M | $427.70M | $1.60M | $432.70M |
| Q3 2023Sep 30, 2023 | $45.40M | $422.20M | $4.30M | $429.60M |
| Q2 2023Jun 30, 2023 | $60.20M | $403.30M | $6.40M | $416.00M |
| Q1 2023Mar 31, 2023 | $45.40M | $361.80M | $1.60M | $367.40M |
| Q4 2022Dec 31, 2022 | $46.50M | $372.60M | $4.90M | $380.60M |
| Q3 2022Sep 30, 2022 | $45.30M | $361.40M | $5.10M | $369.50M |
| Q2 2022Jun 30, 2022 | $72.40M | $339.20M | $7.90M | $349.60M |
| Q1 2022Mar 31, 2022 | $45.70M | $302.80M | $7.50M | $314.10M |
| Q4 2021Dec 31, 2021 | $148.50M | $295.10M | $7.60M | $305.80M |
| Q3 2021Sep 30, 2021 | $65.30M | $259.80M | $3.30M | $266.40M |
| Q2 2021Jun 30, 2021 | $100.90M | $275.60M | $8.60M | $287.20M |
| Q1 2021Mar 31, 2021 | $43.00M | $223.60M | $3.60M | $230.00M |
| Q4 2020Dec 31, 2020 | $69.70M | $196.30M | $4.00M | $203.50M |
| Q3 2020Sep 30, 2020 | $62.50M | $159.60M | $9.00M | $171.60M |
| Q2 2020Jun 30, 2020 | $80.70M | $173.60M | $5.10M | $181.20M |
| Q1 2020Mar 31, 2020 | $33.00M | $189.20M | $4.70M | $196.60M |
| Q4 2019Dec 31, 2019 | $45.40M | $181.10M | $13.80M | $197.30M |

